Opendata, web and dolomites

CONQUEST

Companion Nanodiagnostics for Quantifying EPR and Stratifying Patients to Targeted Nanotherapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CONQUEST" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAETSKLINIKUM AACHEN 

Organization address
address: Pauwelsstrasse 30
city: AACHEN
postcode: 52074
website: www.ukaachen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 145˙312 €
 EC max contribution 145˙312 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) coordinator 145˙312.00

Map

 Project objective

CONQUEST aims to commercialise a first-of-its-kind platform technology for imaging a biological effect – i.e. the EPR effect – that is predictive for a cancer patient's response to tumor-targeted nanomedicine (NM) therapy. CONQUEST thereby addresses a key issue in the (nano)pharmaceutical industry; as currently large proportions of cancer patients do not respond to NM, while others show major improvements in terms of response rates, survival times and quality of life. This trend impairs the outcome of clinical studies and results in many patients receiving treatments that are not effective to them. It would therefore be highly desirable to stratify responders from non-responders prior to study entry or treatment. CONQUEST stands at the basis of introducing a solution to this problem in the pharmaceutical industry. Prof. Lammers and colleagues, as part of ERC-funded research, have developed a powerful imaging approach that allows to construct an EPR profile of each individual tumour - by the administration and non-invasive imaging of contrast agent-labelled nanocarriers (drug-loaded or empty) that accumulate in tumours through EPR. The general idea is that patients with a low degree of EPR, and therefore unlikely to respond to such treatments, can be excluded from NM treatment and referred to alternative established or experimental interventions. Vice versa, patients with a high level of EPR can likely be treated relatively efficiently. Recognising the commercial potential of this technology, CONQUEST aims to tailor the technique and protocol for application in humans, by tuning the method for imaging with PET-MRI. A successful demonstration of PET-MRI-based EPR imaging will trigger large interest of the pharmaceutical and diagnostics industry, to invest in further clinical (co-) development.

 Publications

year authors and title journal last update
List of publications.
2016 Twan Lammers, Fabian Kiessling, Marianne Ashford, Wim Hennink, Daan Crommelin, Gert Strom
Cancer nanomedicine: is targeting our target?
published pages: 16069, ISSN: 2058-8437, DOI: 10.1038/natrevmats.2016.69
Nature Reviews Materials 1/9 2019-07-22
2017 Yang Shi, Twan Lammers, Gert Storm, Wim E. Hennink
Physico-Chemical Strategies to Enhance Stability and Drug Retention of Polymeric Micelles for Tumor-Targeted Drug Delivery
published pages: 1600160, ISSN: 1616-5187, DOI: 10.1002/mabi.201600160
Macromolecular Bioscience 17/1 2019-07-22
2017 Bart J. Crielaard, Twan Lammers, Stefano Rivella
Targeting iron metabolism in drug discovery and delivery
published pages: 400-423, ISSN: 1474-1776, DOI: 10.1038/nrd.2016.248
Nature Reviews Drug Discovery 16/6 2019-07-22
2017 Jennifer I. Hare, Twan Lammers, Marianne B. Ashford, Sanyogitta Puri, Gert Storm, Simon T. Barry
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
published pages: 25-38, ISSN: 0169-409X, DOI: 10.1016/j.addr.2016.04.025
Advanced Drug Delivery Reviews 108 2019-07-22
2017 Alexandra G. Arranja, Vertika Pathak, Twan Lammers, Yang Shi
Tumor-targeted nanomedicines for cancer theranostics
published pages: 87-95, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2016.11.014
Pharmacological Research 115 2019-07-22
2017 Tarun Ojha, Vertika Pathak, Yang Shi, Wim E. Hennink, Chrit T.W. Moonen, Gert Storm, Fabian Kiessling, Twan Lammers
Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors
published pages: , ISSN: 0169-409X, DOI: 10.1016/j.addr.2017.07.007
Advanced Drug Delivery Reviews 2019-07-22
2017 Qingxue Sun, Tarun Ojha, Fabian Kiessling, Twan Lammers, Yang Shi
Enhancing Tumor Penetration of Nanomedicines
published pages: 1449-1459, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.7b00068
Biomacromolecules 18/5 2019-07-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONQUEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONQUEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SUBMODULAR (2019)

The Power of Randomness and Continuity in Submodular Optimization

Read More  

CARBOFLOW (2020)

Streamlined carbon dioxide conversion in ionic liquids – a platform strategy for modern carbonylation chemistry

Read More